糖皮質激素
Glucocorticoids
Corticosteroids
別名: Prednisone · Dexamethasone · Hydrocortisone · Methylprednisolone · Kenalog · Recicort · Glucocorticosteroids · Triamcinolone acetonide
由 VetSheet 獸醫團隊審訂更新於 2026年4月5日本內容以實證獸醫文獻為本
劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。
各物種劑量
🌎 NA — North America🌍 EU — Europe
狗
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Anti-inflammatory (Prednisolone equivalent) | 0.5-1.0 mg/kg | PO | q12h to q24h | Taper to lowest effective alternate-day dose | 🌍 EU |
| Immunosuppressive (Prednisolone equivalent) | 2.0-4.0 mg/kg | PO | q24h (divided q12h initially) | Taper slowly over weeks to months | 🌍 EU |
- Anti-inflammatory (Prednisolone equivalent): Doses are highly variable depending on the specific glucocorticoid used.
- Immunosuppressive (Prednisolone equivalent): Monitor closely for severe adverse effects at these doses.
貓
| 適應症 | 劑量 | 途徑 | 頻次 | 療程 | 地區 |
|---|---|---|---|---|---|
| Anti-inflammatory (Prednisolone equivalent) | 1.0-2.0 mg/kg | PO | q12h to q24h | Taper to lowest effective alternate-day dose | 🌍 EU |
| Immunosuppressive (Prednisolone equivalent) | 2.0-4.0 mg/kg | PO | q12h to q24h | Taper slowly over weeks to months | 🌍 EU |
- Anti-inflammatory (Prednisolone equivalent): Cats require higher doses than dogs and should receive prednisolone, not prednisone.
- Immunosuppressive (Prednisolone equivalent): Monitor for signs of diabetes mellitus.
劑量為持牌獸醫專業人員的臨床參考。請務必對照最新藥品說明書及個別病患確認。
概覽
糖皮質激素是一大類對哺乳動物幾乎所有細胞類型和系統都有深遠影響的類固醇激素。在獸醫學中，它們主要用於四個廣泛的劑量範圍和適應症：
- 生理性替代療法： 用於腎上腺功能不全（如愛迪生氏症）的病患。
- 抗發炎： 用於控制過敏狀態、呼吸道疾病（氣喘）、皮膚病和骨關節炎。
- 免疫抑制： 用於自體免疫疾病，如免疫介導性溶血性貧血 (IMHA)、血小板低下症、天皰瘡和全身性紅斑狼瘡。
- 抗腫瘤： 在某些腫瘤（如淋巴瘤）中作為細胞毒性藥物使用。
臨床要點： 貓通常需要比狗更高的劑量才能達到相同的臨床效果，但對產生副作用的抵抗力較強。相反，狗對糖皮質激素高度敏感，長期使用極易引發醫源性腎上腺皮質機能亢進（庫興氏症候群）。
作用機制
Glucocorticoids exert their effects primarily by binding to cytosolic glucocorticoid receptors (GR). The receptor-ligand complex translocates to the nucleus, where it binds to glucocorticoid response elements (GREs) on DNA, altering gene transcription (transactivation and transrepression).
- Anti-inflammatory Pathway: They induce the production of lipocortin (annexin-1), which inhibits phospholipase A2. This blocks the release of arachidonic acid from cell membranes → dramatically decreasing the synthesis of both prostaglandins and leukotrienes.
- Immune Suppression: They inhibit macrophage function, decrease circulating T-lymphocytes, suppress inflammatory cytokines (IL-1, IL-6, TNF-alpha), and inhibit the complement cascade.
- Metabolic Effects: Stimulate gluconeogenesis, mobilize amino acids, and redistribute adipose tissue, which can lead to insulin resistance.
安全性與警告
禁忌症
- Systemic fungal infections (unless used for physiologic replacement)
- Intramuscular administration in patients with idiopathic thrombocytopenia
- Known hypersensitivity to the specific compound
- Chronic use of sustained-release injectables for systemic diseases
- Concurrent use with NSAIDs (relative contraindication due to severe GI ulcer risk)
- Pregnant animals
- Renal disease (systemic use)
- Diabetes mellitus (systemic use)
- Corneal ulcers
- Concurrent use of NSAIDs
- Uncontrolled diabetes mellitus
- Late pregnancy (may induce abortion or parturition)
不良反應
- Polyuria (PU), polydipsia (PD), and polyphagia (PP)
- Weight gain and fat redistribution
- Panting (especially in dogs)
- Dull, dry haircoat and alopecia
- Vomiting and diarrhea
- Gastrointestinal ulceration
- Elevated liver enzymes (ALP > ALT) and vacuolar hepatopathy (dogs)
- Pancreatitis
- Insulin resistance leading to or worsening diabetes mellitus
- Muscle wasting and weakness
- Behavioral changes (depression, lethargy, viciousness)
- Iatrogenic hyperadrenocorticism (Cushing's syndrome) with chronic use
- Laminitis (horses)
- Hypothalamic-pituitary axis (HPA) suppression
- Adrenal atrophy
- Weight loss (catabolic effect)
- Cutaneous atrophy
- Diarrhoea
- Increased urine glucose levels
- Decreased serum T3 and T4 values
- Impaired wound healing
- Delayed recovery from infections
- Muscle weakness
- Obesity
- Thromboembolic disease
- Polyuria and polydipsia (PU/PD)
- Muscle atrophy and weakness
- Alopecia and thin skin
- Insulin resistance and secondary diabetes mellitus
- Immunosuppression and increased susceptibility to infections
- Hepatomegaly and elevated liver enzymes (steroid hepatopathy in dogs)
注意事項
Animals receiving systemic glucocorticoids (other than short-term 'burst' therapy) MUST be tapered off the drugs slowly to allow endogenous ACTH and corticosteroid function to return. Abrupt withdrawal can precipitate a life-threatening Addisonian crisis. During periods of stress (e.g., surgery, trauma, severe illness) during the tapering process, additional glucocorticoids should be administered. Use with caution in young, growing animals as it can retard bone growth.
藥物相互作用
May cause hypokalemia when administered concomitantly
May lead to profound muscle weakness in myasthenia gravis patients; discontinue 24h prior if possible
Glucocorticoids may reduce salicylate blood levels; increased risk of GI ulceration
Glucocorticoids may inhibit hepatic metabolism of cyclophosphamide
May mutually inhibit hepatic metabolism, increasing blood levels of both drugs
Increased risk for arrhythmias secondary to glucocorticoid-induced hypokalemia
May cause additive hypokalemia
May increase glucocorticoid metabolism
May potentiate the effects of hydrocortisone and possibly other glucocorticoids
Insulin requirements may increase due to glucocorticoid-induced insulin resistance
May decrease glucocorticoid metabolism
May alter steroid metabolism; higher steroid doses may be necessary to treat mitotane-induced adrenal insufficiency
Significantly increased risk of severe gastrointestinal ulceration
May increase the metabolism of glucocorticoids
May increase the metabolism of glucocorticoids
May increase the metabolism of glucocorticoids
Live attenuated vaccines should be avoided due to augmented virus replication; diminished immune response to all vaccines may occur
Hypokalaemia may develop
Decreased metabolism of corticosteroids
Significantly increased risk of severe gastrointestinal ulceration and perforation.
Increased risk of hypokalemia due to additive potassium-wasting effects.
監測
- Weight, appetite, and signs of edema
- Serum and/or urine electrolytes (potassium, calcium, sodium)
- Total plasma proteins and albumin
- Liver enzymes (ALP, ALT, GGT)
- Growth and development in young animals
- ACTH stimulation test (if assessing adrenal recovery or iatrogenic Cushing's)
- Clinical signs of hyperadrenocorticism
- Blood glucose (especially in diabetics)
- Thyroid panel (T3/T4 may decrease)
- Clinical signs of PU/PD and weight gain
- Blood glucose (due to diabetes mellitus risk)
- ACTH stimulation test (to monitor HPA axis suppression)
- Water intake and urine output
- Appetite and body weight
- Blood glucose (especially in cats)
- Liver enzymes (ALP is typically markedly elevated in dogs on steroids)
- Clinical signs of secondary infections (e.g., UTI, pyoderma)
- Gastrointestinal signs (vomiting, melena)
藥物動力學
半衰期
吸收
Varies significantly by ester formulation. Sodium succinate/phosphate esters are absorbed very rapidly (minutes). Acetate esters are absorbed moderately (days to weeks). Acetonide esters are absorbed poorly (weeks).
分佈
Widely distributed. Unbound glucocorticoids can enter milk and cross the placenta.
代謝
Primarily hepatic metabolism.
排除
Metabolites are primarily excreted by the kidneys.
過量
Short-term massive overdoses are unlikely to cause acute harmful effects, though one case of acute CNS effects in a dog has been reported (treat supportively). Chronic overdosage leads to serious adverse effects manifesting as iatrogenic hyperadrenocorticism (Cushing's syndrome).
可用產品
劑型
- Oral tablets and liquids
- Injectable solutions (e.g., sodium succinate/phosphate esters for rapid onset)
- Injectable suspensions (e.g., acetate/acetonide esters for sustained release)
- Topical creams, ointments, and sprays
- Ophthalmic drops and ointments
- Injectable: 40 mg/ml suspension for deep i.m., intra-articular or intralesional use
- Topical: Solution containing 1.77 mg/ml with 17.7 mg/ml salicylic acid
- Systemic (Oral/Injectable)
- Local
- Inhaled
- Oral liquids
- Injectable solutions (e.g., sodium phosphate salts)
- Injectable suspensions (e.g., acetate or acetonide salts)
獸醫用
- Kenalog 40 mg/ml injectable suspension
- Recicort 1.77 mg/ml topical solution
- Prednicare (Prednisolone tablets)
- Dexadreson (Dexamethasone injection)
- Moderin (Methylprednisolone tablets)
人用標示
- Prednisolone tablets
- Dexamethasone tablets/injection
- Hydrocortisone tablets
各地核准狀態
停藥期: cattle meat Varies by specific drug and formulation
Widely approved across member states.
POM-V classification.
暫無法規資料: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU
儲存與穩定性
Store according to specific product labeling, generally at room temperature away from light and moisture.
飼主須知
極度重要警告： 除非獸醫師特別指示，否則絕對不要突然停藥。您的寵物在服藥期間身體會停止自行製造類固醇，突然停藥可能會引發危及生命的危機。
- 預期變化： 寵物（尤其是狗）在服藥期間喝水量增加、排尿頻繁和食慾大增是非常常見的。請確保牠們隨時有乾淨的飲水，並增加帶牠們上廁所的頻率。
- 喘氣： 狗狗可能會過度喘氣；這是一個常見的副作用。
- 行為改變： 有些寵物可能會變得昏昏欲睡、抑鬱或異常易怒。
- 何時該聯繫獸醫師： 如果您發現寵物嚴重嘔吐、排出黑色/柏油狀糞便（胃潰瘍的徵兆）、極度虛弱，或者口渴/排尿增加的情況變得難以控制，請立即聯繫您的獸醫師。
VetSheet 藥物參考供持牌獸醫專業人員作臨床決策輔助之用，不能取代專業判斷或廠方最新藥品說明書。